SynthesisPeerJ2026
Comparing efficacy and safety of oral drugs in treatment of hyperthyroidism: a systematic review and network meta-analysis.
Synthesis in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyrotoxicosis refers to a condition where there is an excess of thyroid hormone production by the thyroid gland itself, leading to a form of hyperthyroidism. Objective: This study is based on systematic review and network meta-analysis methods, aiming to provide a more reliable basis for the selection of clinical treatment plans by comprehensively considering the efficacy and safety of different drugs in treating hyperthyroidism, including the regulation of thyroid hormone levels and potential adverse reactions. Methods: Computerized searches were conducted in eight major domestic and international databases (PubMed, Cochrane Library, Embase, Web of Science, CBM, CNKI, WANFANG DATA, VIP) for randomized controlled trials (RCTs) on the efficacy of oral medications in improving the treatment outcomes of patients with hyperthyroidism. The search period covered from the inception of each database to October 2025. All researchers independently screened the literature, extracted data, and assessed the quality of the studies. For studies meeting the quality criteria, data analysis was performed using Stata 17.0 and RevMan 5.4 software. Results: A total of 151 articles were ultimately included, involving 14,158 patients, with 7,084 in the treatment group and 7,074 in the control group. The network meta-analysis showed that in terms of total effective rate, the top three interventions with the highest Surface Under the Cumulative Ranking Curve (SUCRA) probability ranking curve area were I-131 (Iodine-131)+LC (lithium carbonate), MMI (Methimazole)+PHT (Propranolol), and I-131; in terms of reducing Free Triiodothyronine (FT3), the top three interventions with the highest SUCRA probability ranking curve area were MMI+PDN (prednisone), I-131+LC, and I-131; in terms of reducing free tetraiodothyronine (FT4), the top three interventions with the highest SUCRA probability ranking curve area were I-131+PTU (Propylthiouracil), I-131+LC, and I-131; in terms of increasing thyroid-stimulating hormone (TSH), the top three interventions with the highest SUCRA probability ranking curve area were I-131+PTU, I-131, and MMI+PDN; in terms of reducing adverse reactions, the top three interventions with the highest SUCRA probability ranking curve area were I-131+PTU, I-131, and I-131+MMI. Conclusion: This study indicates that among the interventions for treating hyperthyroidism, I-131+LC has a higher efficacy rate compared to other treatments, I-131+PTU is superior in reducing FT3, increasing TSH and reducing adverse reactions compared to other treatments. Due to the limitations in the quantity and quality of the included studies, the aforementioned conclusions await further validation from more large-sample, high-quality, and multicenter studies. PROSPERO study number CRD42024566298.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.